Literature DB >> 29195810

Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.

Gianna Triller1, Stephen W Scally2, Giulia Costa3, Maria Pissarev3, Cornelia Kreschel3, Alexandre Bosch2, Eric Marois4, Brandon K Sack5, Rajagopal Murugan1, Ahmed M Salman6, Chris J Janse7, Shahid M Khan7, Stefan H I Kappe5, Ayola A Adegnika8, Benjamin Mordmüller9, Elena A Levashina3, Jean-Philippe Julien10, Hedda Wardemann11.   

Abstract

Antibodies against the NANP repeat of circumsporozoite protein (CSP), the major surface antigen of Plasmodium falciparum (Pf) sporozoites, can protect from malaria in animal models but protective humoral immunity is difficult to induce in humans. Here we cloned and characterized rare affinity-matured human NANP-reactive memory B cell antibodies elicited by natural Pf exposure that potently inhibited parasite transmission and development in vivo. We unveiled the molecular details of antibody binding to two distinct protective epitopes within the NANP repeat. NANP repeat recognition was largely mediated by germline encoded and immunoglobulin (Ig) heavy-chain complementarity determining region 3 (HCDR3) residues, whereas affinity maturation contributed predominantly to stabilizing the antigen-binding site conformation. Combined, our findings illustrate the power of exploring human anti-CSP antibody responses to develop tools for malaria control in the mammalian and the mosquito vector and provide a molecular basis for the structure-based design of next-generation CSP malaria vaccines.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Plasmodium falciparum; X-ray structures; affinity maturation; circumsporozoite protein; epitope specificity; human; malaria; memory B cells; natural infection; protective antibodies

Mesh:

Substances:

Year:  2017        PMID: 29195810      PMCID: PMC5738265          DOI: 10.1016/j.immuni.2017.11.007

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  71 in total

1.  Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of Plasmodium falciparum by 1H NMR.

Authors:  H J Dyson; A C Satterthwait; R A Lerner; P E Wright
Journal:  Biochemistry       Date:  1990-08-28       Impact factor: 3.162

2.  Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum.

Authors:  Arin Ghasparian; Kerstin Moehle; Anthony Linden; John A Robinson
Journal:  Chem Commun (Camb)       Date:  2005-11-21       Impact factor: 6.222

3.  Two mosquito LRR proteins function as complement control factors in the TEP1-mediated killing of Plasmodium.

Authors:  Malou Fraiture; Richard H G Baxter; Stefanie Steinert; Yogarany Chelliah; Cécile Frolet; Wilber Quispe-Tintaya; Jules A Hoffmann; Stéphanie A Blandin; Elena A Levashina
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

4.  Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite.

Authors:  N Yoshida; R S Nussenzweig; P Potocnjak; V Nussenzweig; M Aikawa
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

5.  Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens.

Authors:  Gregory S Noland; Paul Jansen; John M Vulule; Gregory S Park; Bartholomew N Ondigo; James W Kazura; Ann M Moormann; Chandy C John
Journal:  Acta Trop       Date:  2014-10-24       Impact factor: 3.112

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

Authors:  Chandy C John; Aaron J Tande; Ann M Moormann; Peter O Sumba; David E Lanar; Xinan M Min; James W Kazura
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

8.  The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.

Authors:  Michael T White; Philip Bejon; Ally Olotu; Jamie T Griffin; Eleanor M Riley; Kent E Kester; Christian F Ockenhouse; Azra C Ghani
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

9.  Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies.

Authors:  Matthias F Muellenbeck; Beatrix Ueberheide; Borko Amulic; Alexandra Epp; David Fenyo; Christian E Busse; Meral Esen; Michael Theisen; Benjamin Mordmüller; Hedda Wardemann
Journal:  J Exp Med       Date:  2013-01-14       Impact factor: 14.307

10.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Authors:  Bryan Briney; Devin Sok; Joseph G Jardine; Daniel W Kulp; Patrick Skog; Sergey Menis; Ronald Jacak; Oleksandr Kalyuzhniy; Natalia de Val; Fabian Sesterhenn; Khoa M Le; Alejandra Ramos; Meaghan Jones; Karen L Saye-Francisco; Tanya R Blane; Skye Spencer; Erik Georgeson; Xiaozhen Hu; Gabriel Ozorowski; Yumiko Adachi; Michael Kubitz; Anita Sarkar; Ian A Wilson; Andrew B Ward; David Nemazee; Dennis R Burton; William R Schief
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more
  54 in total

1.  Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.

Authors:  Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  B cell profiling in malaria reveals expansion and remodelling of CD11c+ B cell subsets.

Authors:  Christopher Sundling; Caroline Rönnberg; Victor Yman; Muhammad Asghar; Peter Jahnmatz; Tadepally Lakshmikanth; Yang Chen; Jaromir Mikes; Mattias N Forsell; Klara Sondén; Adnane Achour; Petter Brodin; Kristina Em Persson; Anna Färnert
Journal:  JCI Insight       Date:  2019-04-02

Review 3.  Malaria vaccines since 2000: progress, priorities, products.

Authors:  Patrick E Duffy; J Patrick Gorres
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

4.  A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.

Authors:  Lawrence T Wang; Lais S Pereira; Yevel Flores-Garcia; James O'Connor; Barbara J Flynn; Arne Schön; Nicholas K Hurlburt; Marlon Dillon; Annie S P Yang; Amanda Fabra-García; Azza H Idris; Bryan T Mayer; Monica W Gerber; Raphael Gottardo; Rosemarie D Mason; Nicole Cavett; Reid B Ballard; Neville K Kisalu; Alvaro Molina-Cruz; Jorgen Nelson; Rachel Vistein; Carolina Barillas-Mury; Rogerio Amino; David Baker; Neil P King; Robert W Sauerwein; Marie Pancera; Ian A Cockburn; Fidel Zavala; Joseph R Francica; Robert A Seder
Journal:  Immunity       Date:  2020-09-17       Impact factor: 31.745

5.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

6.  Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity.

Authors:  Vincent van Unen; Mikhael D Manurung; Koen A Stam; Sanne E de Jong; Jelle J Goeman; Simon P Jochems; Thomas Höllt; Nicola Pezzotti; Yoanne D Mouwenda; Madeleine Eunice Betouke Ongwe; Freia-Raphaella Lorenz; Yvonne C M Kruize; Shohreh Azimi; Marion H König; Anna Vilanova; Elmar Eisemann; Boudewijn P F Lelieveldt; Meta Roestenberg; B Kim Lee Sim; Marcel J T Reinders; Rolf Fendel; Stephen L Hoffman; Peter G Kremsner; Frits Koning; Benjamin Mordmüller; Bertrand Lell; Maria Yazdanbakhsh
Journal:  Nat Immunol       Date:  2021-04-22       Impact factor: 25.606

7.  Potent Virustatic Polymer-Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo.

Authors:  Adrian Najer; Joshua Blight; Catherine B Ducker; Matteo Gasbarri; Jonathan C Brown; Junyi Che; Håkon Høgset; Catherine Saunders; Miina Ojansivu; Zixuan Lu; Yiyang Lin; Jonathan Yeow; Omar Rifaie-Graham; Michael Potter; Renée Tonkin; Jelle Penders; James J Doutch; Athina Georgiadou; Hanna M G Barriga; Margaret N Holme; Aubrey J Cunnington; Laurence Bugeon; Margaret J Dallman; Wendy S Barclay; Francesco Stellacci; Jake Baum; Molly M Stevens
Journal:  ACS Cent Sci       Date:  2022-05-03       Impact factor: 18.728

8.  Germinal center activity and B cell maturation are associated with protective antibody responses against Plasmodium pre-erythrocytic infection.

Authors:  Ganesh Ram R Visweswaran; Kamalakannan Vijayan; Ramyavardhanee Chandrasekaran; Olesya Trakhimets; Samantha L Brown; Vladimir Vigdorovich; Ashton Yang; Andrew Raappana; Alex Watson; William Selman; Meghan Zuck; Nicholas Dambrauskas; Alexis Kaushansky; D Noah Sather
Journal:  PLoS Pathog       Date:  2022-07-06       Impact factor: 7.464

Review 9.  Antibodies against Plasmodium falciparum malaria at the molecular level.

Authors:  Jean-Philippe Julien; Hedda Wardemann
Journal:  Nat Rev Immunol       Date:  2019-08-28       Impact factor: 53.106

10.  Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice.

Authors:  Katherine L Mallory; Justin A Taylor; Xiaoyan Zou; Ishita N Waghela; Cosette G Schneider; Michael Q Sibilo; Neeraja M Punde; Leah C Perazzo; Tatyana Savransky; Martha Sedegah; Sheetij Dutta; Chris J Janse; Norbert Pardi; Paulo J C Lin; Ying K Tam; Drew Weissman; Evelina Angov
Journal:  NPJ Vaccines       Date:  2021-06-18       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.